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Abstract
Expression of MHC class II, DM and li genes is controlled by the transactlvator CIITA, a mediator of
the activation of these genes by IFN-y. Surprisingly, MHC class II molecules expressed on CIITA
transfectants behave very differently from those expressed at the same level on IFN-y-induced cells
in terms of peptide binding and peptide-specific T cell activation. MHC class ll-posltlve CIITA
transfectants exhibit an unusually high capacity for binding exogenous peptldes, with a higher
percentage of DR molecules occupied by a given peptide and are much more efficient at peptide-
specific, HLA-DR-restricted activation of T lymphocytes. This unexpected phenotype reflects the
antigen processing defect observed in CIITA transfectants. It suggests novel strategies for the use
of CIITA-transformed cells in peptide-based Immunization.
Introduction
Activation of CD4+ antigen-specific T cells depends on the
recognition by the TCR of specific complexes of peptides
and MHC class II molecules displayed at the surface of
antigen-presenting cells (APC). The formation of these com-
plexes is a complicated process that favors presentation of
peptide antigens derived from exogenous proteins. On their
way to the cell surface, newly synthesized MHC class II
invariant chain (li) complexes egress from the endoplasmic
reticulum to a specialized endosomal compartment where,
following removal of the li chain, they are loaded with peptides
generated by the denaturation and proteolysis of endocytosed
protein antigens (1,2) This complex peptide loading process
requires the participation of HLA-DM molecules (3-5).
This essential role of MHC class II molecules for T cell
activation implies that the very tight regulation of their expres-
sion in various cell types represents an important level of
control It is now established that both constitutive expression
of MHC class II genes in specialized cells such as B lympho-
cytes and their inducible expression in certain other cell types
are under the control of the MHC class II transactivator CIITA
(6,7). In MHC class ll-negative cells, CIITA is necessary for
the induction of class II genes by IFN-y and is sufficient, in
the absence of IFN-y, to turn on MHC class II expression (7).
CIITA also controls the expression of the li and HLA-DM
genes (8,9). Surprisingly, however, when cells rendered MHC
class ll-positive by either IFN-yor by transfection with CIITA,
and expressing the same level of class II molecules, were
compared for their ability to present exogenous protein anti-
gens to specific CD4+ T cell clones, it was observed that
IFN-7-treated cells could indeed activate T cells, whereas
CIITA transfectants were unable to do so (10). This defect
occurs at the level of antigen processing, through a yet
undefined mechanism that can be corrected by treating the
CIITA transfectants with IFN-y.
We have now compared the properties of MHC class II
molecules expressed respectively on processing-defective
CIITA-transfected cells and on IFN--y-induced cells for their
ability to activate peptide-specific HLA-DR-restricted T cell
lines. A drastic difference was observed in these two MHC
class ll-positive cells: CIITA transfectants are much more
efficient at peptide binding and a higher percentage of their
surface MHC class II molecules can be loaded with a given
specific peptide. Importantly, this results in a much more
efficient peptide-specific, HLA-DR-restricted T cell activation
than observed with IFN-y-treated cells. The data suggests
that MHC class li-positive CIITA transfectants, once pulsed
with selected peptide antigens, could be of interest for novel
peptide-based immunization strategies.
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Methods
Cells and culture conditions
Human melanoma cells Me67 and Me208 and Epstein-Barr
virus (EBV)-transformed lines OMW and BOLETH (11) were
grown in RPMI 1640 medium complemented with glutamine,
10% heat-inactivated (56°C) FCS and antibiotics. Cells were
incubated at 37°C in 5% CO2 and maintained in logarithmic
growth phase with a viability >98% at all steps. For MHC
class II induction, melanoma cells were incubated with human
recombinant IFN-y (sp. act. 1.4X107 U/mg; a gift of Biogen,
Cambridge, MA) at 500 U/ml for a 48 h period.
Transfections
Melanoma cell lines were transfected by calcium phosphate
precipitation followed 4 h later by a glycerol shock with either
the expression vector EBO-Sfi alone or a full-length CIITA
cDNA cloned into EBO-Sfi under control of the SV40 promoter
(6,7). Stable transfectants were generated by selection with
hygromycin B (Calbiochem, La Jolla, CA) and maintained in
culture with hygromycin throughout the study, including during
IFN-y induction. Identical results were obtained with untrans-
fected cells and cells transfected with the vector alone All
studies were performed with bulk cultures rather than clones,
thereby excluding the possible aberrant behavior of a single
transfectant clone.
Surface MHC class II expression
Duplicate samples of 2x 105 cells were washed, pre-adsorbed
with 10% normal rabbit serum (NRS), incubated with NRS or
polymorphic HLA-DR mAb 2.06 (12) followed by fluorescein-
conjugated rabbit anti-mouse IgG (Serotec), washed and
analyzed by flow cytometry on a FACSan analyzer (Becton
Dickinson, Mountain View, CA). Viable cells were gated based
on propidium iodide uptake. A total of 10,000 cells were
analyzed for each determination. The data were analyzed by
the Lysys software package.
T cell lines
T61, T50, T54 and T87 are T cell lines specific for the p4
peptide of tetanus toxin (tt 1273-1284) which are restricted
by the DRB3*0101 allele (data not shown). T19 is a T cell line
specific for the p2 peptide of tetanus toxin (tt 830-843) which
is restricted by DRB1*11 and DRB1*8 alleles (13). RPMI
1640 supplemented with 15% human AB+ serum from male
volunteer donors was used as culture medium. T cell lines
were re-stimulated for expansion with autologous irradiated
peripheral blood mononuclear cells, preincubated with p4 or
p2 peptides, in IL-2-supplemented culture medium. Expanded
T cell lines were frozen in culture medium-DMSO 10% and
stored in liquid nitrogen (13).
Antigen presentation to T cells
Melanoma cells (106) were fixed with 0.2% paraformaldehyde,
washed and preincubated with various concentrations of
tetanus synthetic peptides prior to washing and use as APC
(3x104 cells/well) in co-culture with tetanus-specific T cell
lines (2X104 cells/well) as described (10). The prohferative
response of tetanus-specific T cell lines was measured after
48 h by [3H]thymidine incorporation.
Peptide binding
Binding assays were performed as described (14,15). Briefly,
3X105 melanoma, either CIITA transfected or IFN-Y-treated,
and EBV-transformed cell lines were incubated at 37°C for 4 h
with various concentrations of a biotmylated peptide (HA307-
319) of the influenza hemagglutmin (14) or medium alone. In
competition experiments, cells were first incubated with a
large excess of non-biotinylated HA peptide After washing,
cells were incubated with FITC-streptavidin (4.22 ng/ml;
Calbiochem) at 4°C for 30 mm. Stained cells were washed
again and analyzed by flow cytometry as described above.
To determine the relative amount of HLA-DR expressed on
the surface of the cell lines, cells were incubated with a FITC-
labeled munne mAb specific for DR (L243, Becton Dickinson)
The fluorescein:protein ratios indicated by manufacturers
were used to estimate the amount of cell surface DR. The
effects of variations in DR expression between different cell
lines were eliminated by dividing the fluorescence obtained
with biotmylated peptide and fluoresceinated streptavidm by
the level of staining with directly conjugated L243 (14).
Assuming similar fluoresceinprotein ratios for both labeled
reagents and stoichiometric binding, this ratio was interpreted
as the estimate of the fraction of DR molecules occupied by
peptides.
Results
Peptide binding on surface MHC class II molecules
Indirect immunofluorescence analysis was first used to con-
firm that IFN-Y- ancJ CIITA-transfected melanoma cells (Me67)
express identical levels of surface HLA-DR molecules (Fig.
1B and C). It was also shown elsewhere (10) that the rate of
newly made HLA-DR chains is identical under both conditions,
and that both li and HLA-DM are induced in CIITA transfec-
tants. When these two types of cells were incubated with a
biotinylated influenza peptide (HA307-319) known to bind to
HLA-DR4 (14), prior to addition of FITC-streptavidin, a drastic
difference in peptide binding was observed (Fig 1, lower
panel). Little staining above auto-fluorescence was detected
on IFN-y-treated Me67 cells (Fig. 1G), which is consistent
with peptide binding by <2% of surface HLA-DR molecules.
In contrast, peptide binding on CIITA-transfected Me67 cells
expressing similar levels of MHC class II molecules increased
several fold as compared with IFN-Y-treated cells (Fig. 1H).
CIITA transfectants were then compared with homozygous
EBV-transformed B cell lines, known to express unusually
high densities of surface HLA-DR. HLA-DR4 and -DR13
homozygous cell lines (11) were chosen to match the two
HLA-DR haplotypes expressed by Me67. On these EBV cell
lines, the fluorescent signal resulting from binding of the
HA307-319 peptide (Fig. 11 and J) was similar to that previ-
ously reported by others (14,15). Surprisingly, HLA-DR molec-
ules on CIITA transfectants appeared capable of binding
higher amounts of peptide than EBV-transformed B cells (Fig.
1H). The greater total peptide binding capacity of MHC class
ll-positive CIITA transfectants as compared to both IFN-Y-
treated cells and B cell lines was confirmed in dose-response
experiments (Fig. 2a). Competition assays in which cells were
first incubated with a 10-fold excess of non-biotinylated
Me67
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Fig 1. Peptide binding to MHC class II molecules at the surface of APC (Upper panel) Surface expression of HLA-DR on untransfected Me67
cells (A), Me67 cells incubated with IFN-y(500 U/ml) during 48 h (B), CIITA-transfected Me67 cells (C), EBV-transformed homozygous B cell
lines (B-LCL) expressing HLA-DR4 (D) or DR13 (E) Cells were analyzed by flow cytofluorometry for the expression of HLA-DR (mAb 2 06)
Blank profiles on the left represent cells incubated with NRS and the second reagent alone (Lower panel) Fluorescence of the same cells
incubated with biotinylated HA307-319 peptide (100 (iM) prior to staining with FITC-streptavidm and analysis by flow cytofluorometry Blank
profiles on the left indicate cells incubated with NRS and the second reagent alone Two peaks were observed in the case of the EBV B cell
lines (I and J) that may reflect the presence of two populations of cells
peptide (Fig. 2a) as well as blocking experiments with MHC
class ll-specific antibodies (data not shown) respectively
confirmed peptide and HLA-DR specificity of the cell surface
fluorescence. No binding of HA307-319 peptide was
observed on a panel of MHC class ll-negative cell lines and
on several cell lines expressing HLA-DR alleles that do not
bind this particular peptide (14,15) (data not shown)
Extent of HLA-DR occupancy by a specific peptide
It is known that occupation of MHC class II surface molecules
by multiple peptides strongly limits their capacity to bind a
given specific peptide provided exogenously. Although T cells
have evolved to respond to very small amounts of peptide
antigens (16,17), the heterogeneity of MHC class II occupancy
limits the capacity of APC to be efficiently loaded with specific
peptides. It was therefore of interest to explore if the higher
peptide binding capacity displayed by CIITA transfectants
as compared with IFN-y-treated cells resulted in a higher
percentage of surface HLA-DR molecules capable of binding
a given peptide. This was analyzed according to the approach
previously described by Bush et al. (14). The relative amount
of HLA-DR expressed on the surface of the cell lines was
measured by incubating Me67 cells with FITC-labeled HLA-
DR-specific mAb (L243-FITC; Becton Dickinson) at saturating
concentrations (data not shown). Peptide-specific fluores-
cence was then correlated to surface DR expression and
corrected for respective fluorescein:protein ratios of both
FITC-labeled reagents as described in Methods. The obtained
ratio (Fig. 2b) thus represents an estimate of the fraction of
surface DR molecules occupied by the biotinylated peptide
(14). This estimation indicates that no more than 1% of surface
MHC class II molecules at the surface of EBV-transformed B
cell lines are found to bind a given peptide at a concentration
as high as 100 |iM, in agreement with figures obtained by
others (14,15). This ppDR ratio is at least 50% lower in the
case of MHC class II molecules of the same haplotypes
induced upon IFN-y treatment of Me67 human melanoma
cells. In contrast, the extent of HLA-DR occupancy by the
HA307-319 peptide at the surface of CIITA transfectants was
at least 7-fold higher than that of class II molecules on IFN-
•y-treated cells, at each concentration of peptide.
T cell activation by peptide-pulsed MHC class II molecules
It was obviously of interest to explore the possible functional
implications of the unusually high peptide binding capacity
displayed by DR molecules on CIITA transfectants in terms
of T cell activation CIITA-transfected and IFN-y-treated MHC
class ll-positive cells were compared for their capacity to
present tetanus peptides to tetanus-specific, HLA-DR-
restricted T cell lines. Cells were fixed, preincubated with
tetanus synthetic peptides, washed extensively and used as
APC in co-culture with tetanus-specific T cell lines. The
proliferative response of tetanus-specific T cell lines was
measured after 48 h by [3H]thymidine incorporation. A
dramatic difference in peptide-specific T cell activation was
observed between IFN-y-induced and CIITA-transfected cells
(Fig. 3). The capacity of peptide-pulsed IFN-y-treated Me67
cells to present a tetanus epitope (peptide p4, tt 1273-1284)
to a DRB3*0101-restricted T cell line was either negligible or
low. In contrast, when CIITA-transfected cells expressing the
same levels of MHC class II molecules (Fig, 1) were incubated
with the p4 tetanus peptide, a strong peptide-specific, DR-
restricted activation was observed (Fig. 3A). This increased
capacity of CIITA transfectants, as compared with IFN-y-
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Fig. 2. Relative peptide binding to cell surface HLA-DR molecules
(a) Dose-response analysis Me67 cells (control, IFN-y induced or
CIITA transfected), DR4 and DR13 B-LCLs were incubated with
increasing concentrations of biotmylated HA307-319 peptide prior
to staining with FITC-streptavidin and analysis by flow cytofluorometry
In competition experiments (25+250), cells were first incubated with
an excess of non-biotinylated HA307-319 (250 nM) prior to addition
of biotinylated peptide (25 (iM). Data are expressed as mean
fluorescence intensity after subtraction of background auto-
fluorescence given by cells incubated with NRS and the second
reagent alone (b) Extent of HLA-DR occupancy by a specific peptide
Percentage of HLA-DR molecules estimated to bind biotinylated
HA307-319 at various peptide concentrations Ratios (%) represent
mean fluorescence intensity due to binding of biotinylated peptide
divided by mean anti-HLA-DR fluorescence intensity, after correction
for fluorescence protein ratios of second reagents (14)
treated cells, to activate DR-restricted T cells after incubation
with synthetic peptides was also observed with a different
melanoma cell line (Me208, DRB1*1101/04) presenting a
different tetanus peptide (p2, tt 830-843) to a different T cell
line restricted bytheDRB1*11 and DRB1*08 alleles (Fig. 3B)
Peptide-specific T cell activation was studied further with
four different DRB3*0101-restncted T cell lines and with
various peptide concentrations (Fig. 4). In each case, a sharp
dose-dependent peptide-specific, DR-restricted activation
was observed. The possibility of an antiproliferative effect of
IFN-y on T cells was excluded both by extensive washing of
Me67 cells prior to incubation with T cells and by the capacity
of IFN-y-treated Me67 pulsed with native tetanus protein
antigen to successfully activate the same T cell lines (10)
Discussion
The existence of an antigen processing-defective phenotype
in MHC class ll-positive CIITA transfectants told us that, in
addition to the genes controlled by CIITA, i.e. MHC class II,
li and DM, another activity or protein is required for efficient
presentation of protein antigens (10). Here we report that
MHC class II molecules expressed on the surface of these
antigen presentation-defective CIITA transfectants exhibit an
unusually high affinity for exogenous peptides and that these
peptide loaded non-professional APC become very effective
T cell activators. CIITA transfection of MHC class ll-negative
human melanoma cells induces the expression of surface
MHC class II molecules able to bind and present exogenous
peptides to antigen-specific, DR-restricted T cells to much
higher levels than class II molecules expressed at the surface
of IFN-y-treated cells This is not the consequence of an
additional CIITA-dependant activity, since CIITA expression
is itself induced by IFN-y (6,7).
The essential feature of antigen processing that is missing
in CIITA transfectants, and that can be restored by IFN-y
activation, could concern appropriate trafficking of MHC class
ll-li chain complexes through specific cellular compartments
or the activation of specific proteolytic enzymes required for
adequate peptide loading onto MHC class II molecules
within the endosomal compartment. Whatever the mechanism
responsible for this antigen processing defect, it must lead
to the expression of surface MHC class II molecules that are
not occupied with a normal set of high-affinity peptides This
results in the observed higher peptide binding capacity of
surface MHC class II molecules and explains why CIITA
transfectants exhibit such a high efficacy in T cell activation,
when compared to IFN-y-treated cells.
Expression of the CIITA gene in a non-professional APC
thus converts MHC class ll-negative cells into cells expressing
high levels of autologous MHC class II molecules with an
increased capacity for binding selected exogenous peptides.
In normal cells, the enormous heterogeneity of peptide occu-
pancy of MHC class II binding sites limits their capacity to
bind and present a given peptide to T cells. It is shown here
that, in the case of CIITA transfectants, a significantly higher
proportion of MHC class II molecules can be loaded with a
given specific peptide (Fig. 2b). Since occupation of only
0.1% of HLA-DR molecules by a given peptide has been
shown to be sufficient to trigger T cell activation (16), it is not
surprising that increasing this fraction by several fold results
in a significant increase in peptide-dependant T cell activation.
Peptide loading onto CIITA transfectants can be achieved
with lower concentrations of exogenously provided synthetic
peptides (down to <5 \iM, data not shown). This higher
binding capacity of MHC class II molecules of CIITA transfec-
tants could result either from occupancy of MHC class II
molecules by low-affinity peptides or from the generation of
'empty' class II molecules. Since instability of empty molecules
in SDS-PAGE is only observed with certain specific haplotypes
(18), the normal SDS-PAGE pattern of HLA-DR molecules of
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Fig. 3. Peptide-specific T cell activation by two peptide-pulsed IFN-y-treated and CIITA-transfected melanoma cell lines Me67 and Me208
transfected with CIITA or incubated with IFN-y (500 U/ml) during 48 h were fixed and preincubated overnight with 10 ng/ml p4 (Me67) or p2
(Me208) tetanus toxin peptides Melanoma cells were extensively washed and tested as APC Me67 was tested with p4-specific T cell line
T87 and Me208 was tested with p2-specific, DR11/8-restncted T cell line T19 Results are expressed as c p.m. obtained with peptide-pulsed
melanoma cells after subtraction of c p m obtained with unpulsed melanoma cells
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Fig. 4. Peptide dose-response curve of T cell activation by IFN-y
and CIITA transfected melanoma cells Me67 cells either transfected
with CIITA (solid circles) or incubated with (solid diamonds) or
without (open squares) IFN-y (500 U/ml) during 48 h were fixed and
preincubated overnight with various concentrations of p4 synthetic
tetanus peptide prior to extensive washing and co-culture with T87,
T61, T50 and T54 T cell lines. Results of peptide-specific T cell
proliferation are expressed as the ratio of stimulation obtained with
peptide-pulsed versus non-pulsed Me67 APC
Me67 Cl ITA transfectants (10) does not allow us to discriminate
between these two possibilities.
IFN-Y allows correction of the protein processing defect
seen in CIITA transfectants and thus restores presentation of
a specific protein antigen to T cells (10) Treatment of CIITA
transfectants with IFN-y, however, does not significantly
decrease their high capacity for peptide binding (data not
shown). This observation was indeed expected. The peptide
binding assay measures the overall occupancy of MHC class
II molecules, of which only a fraction will be affected by IFN-Y
treatment Whereas such a fraction of MHC class II molecules
is sufficient to restore presentation of protein antigens (10), it
is not expected to modify the overall capacity of the cell to
bind exogenous peptides.
An interesting analogy can be made between the high
binding capacity of MHC class II molecules observed here
on CIITA transfectants and recent studies of MHC class I
molecules that can be expressed under conditions where
they also exhibit a very high affinity for exogenously provided
peptides (19-21). The antigen processing-defective mutant
cell line RMA-S expresses HLA class I molecules that are
devoid of peptides and that exhibit a high affinity for exogen-
ous peptides (19). It was also observed that, unexpectedly,
transfection of RMA cells with the IL-10 gene lead to an RMA-
S-like phenotype (20). In another system, it was possible to
'strip' experimentally MHC class I molecules on intact cells
and to reload these molecules with exogenous peptides (21).
These peptide-reloaded cells behaved as efficient inducers
of a CD8 cytotoxic T lymphocyte (CTL) response (21).
In the field of tumor immunotherapy, the recent understand-
ing of the importance of an MHC class ll-mediated component
(22-25), together with the discovery of the role of CIITA as a
general regulator of MHC class II expression (7,26), raised
hopes that forcing the expression of CIITA, and consequently
of MHC class II molecules, in tumor cells could lead to novel
tumor immunization strategies. This approach has the obvious
advantage of inducing expression of autologous MHC class
II molecules on patients cells, as opposed to the need to
transfect tumor cells with the relevant MHC class II genes
specific of the particular HLA alleles of each different individual
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(27-30). Our recent description of an antigen processing
defect in MHC class ll-positive, CIITA-transfected melanoma
cells (10) suggests, however, that these cells might not
be that efficient at immunizing against exogenous protein
antigens. Clearly, in vivo vaccination trials will be required to
reach a definite conclusion on this issue.
Since the unusual property of surface MHC class II molec-
ules on CIITA transfectants allows a strong peptide-specific
activation of CD4 T lymphocytes, it might represent a practical
advantage for peptide-based MHC class ll-mediated immun-
ization. This applies to situations where a role of MHC class
ll-mediated CD4 T cell activation and of MHC class ll-specific
tumor antigens in the generation of tumor immunity is demon-
strated or suspected (22,25,27). Two strategies can be envis-
aged to exploit the efficient capacity of CIITA transfectants to
activate T cells. Both have the advantage of dealing with
autologous MHC class II molecules expressed on patient's
cells; both involve CIITA expression, obtained either following
transfection or by the delivery of the CIITA gene by an
appropriate vector system; and both could be combined with
the use of additional genes, such as B7 or granulocyte
macrophage colony stimulating factor (25,30) The first
approach would consist in loading CIITA-transfected, MHC
class ll-positive, autologous tumor cells with specific peptides
derived from proteins that are known to function as MHC
class ll-restricted tumor antigens, such as tyrosinase in the
case of melanoma (22). This would trigger a strong MHC
class ll-specific CD4 T cell response, with the potential for
eliciting CD4 antitumor CTL specific for the tumor antigen
(31,32).
The second strategy relies on the advantage of providing
locally an efficient, peptide-specific, CD4-mediated help
signal that, in turn, could activate anti-tumor CD8 T lympho-
cytes. CIITA-expressing MHC class ll-positive autologous
tumor cells could thus be pulsed with a common promiscuous
peptide antigen, such as a tetanus toxin peptide, and then
used to immunize the same patient. Peptide-specific, HLA-
restricted autologous, CD4 T cells would be activated and
would deliver locally, within the micro-environment of the
tumor cell, the appropriate help signals to bystander genuine
tumor-specific CD8 CTL. It is known that efficient activation of
tumor cell-specific CD8 CTL is facilitated by the simultaneous
activation of CD4 T lymphocytes by the same cell (22). In
addition to cancer immunotherapy, the capacity of inducing
high levels of specific peptide binding and Tcell presentation
by MHC class II molecules could also be relevant to immuniza-
tion programs in various other fields, such as peptide-based
tolerance induction in CD4+ T cell-mediated allergic
responses (33-35).
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APC antigen-presenting cells
CTL cytotoxic T lymphocyte
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h invariant chain
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